If you want to switch to beverages that have lower levels of caffeine than coffee, you could consider green tea
Berkiten G, Yildirim G, Topaloglu I, Ugras H

The ACHIEVE-2 trial compared Foundayo with the sodium-glucose cotransporter-2 (SGLT-2) inhibitor dapagliflozin in 962 adults with inadequate glycemic control on metformin. Participants receiving the highest dose of Foundayo achieved average A1C reductions of up to 1.7%, compared with 0.8% for dapagliflozin after 40 weeks. Additionally, 68.6% of participants receiving the highest dose of Foundayo achieved an A1C goal of 6.5% or lower, compared with 21.6% of those receiving dapagliflozin. In ACHIEVE-5, which evaluated Foundayo in combination with insulin glargine, the oral therapy reduced A1C by up to 2.1% compared with 0.8% for placebo at 40 weeks. Up to 69.1% of participants receiving Foundayo achieved an A1C of 6.5% or lower, compared with 11.1% of participants receiving placebo. Across all three studies, Foundayo also produced clinically meaningful improvements in multiple cardiometabolic risk factors, including cholesterol measures, triglycerides, and systolic blood pressure. Why could oral GLP-1 therapies change diabetes treatment

Schedule your consultation with Dope Doctors today, and lets start your journey toward sustainable weight loss with Semaglutide.
Hayes J, Mclellan L